Skip to main content
Erschienen in: Supportive Care in Cancer 12/2005

01.12.2005 | Original Article

Experience in the use of the palliative care outcome scale

verfasst von: A.-M. Stevens, B. Gwilliam, R. A’Hern, K. Broadley, J. Hardy

Erschienen in: Supportive Care in Cancer | Ausgabe 12/2005

Einloggen, um Zugang zu erhalten

Abstract

Goals of work

The objective of the study is to assess the Palliative Care Outcome Scale (POS) as a potential audit tool within a specialist cancer centre. It also aims to answer the following questions: does the tool identify problem areas and demonstrate changes in quality of life over time? How well do staff and patient ratings correlate?

Patients and methods

The POS questionnaire was piloted at a specialist cancer centre. Thirty consecutive patients admitted to the palliative care wards and ward staff completed questionnaires on admission and twice weekly until discharge or death. A further questionnaire assessed staff attitudes.

Results

There was a significant improvement in overall patient POS score at 1 week (days 5–9). Four “symptoms” or issues were scored as being important for our patients: pain, other symptoms, anxiety and patient’s perception of family anxiety. These all significantly improved within the first week. At the initial assessment, staff underestimated patients’ pain and overestimated problems relating to information giving and patients’ ability to share their feelings. There was no significant difference between staff and patient scores after 1 week. The other six areas covered by the tool were less important; this may reflect the patient population seen at our centre. Use of the tool identified areas for staff training and effectively demonstrated improvement in patient care.

Conclusion

The POS is an outcome measure tool designed to assess physical, psychological, practical and existential aspects of quality of life. It may be useful in identifying problems in individual patients and directing care to address these needs.
Literatur
1.
Zurück zum Zitat Hearn J, Higginson IJ (1997) Outcome measures in palliative care for advanced cancer patients: a review. J Public Health Med 19(2):193–199 Hearn J, Higginson IJ (1997) Outcome measures in palliative care for advanced cancer patients: a review. J Public Health Med 19(2):193–199
2.
Zurück zum Zitat Hearn J, Higginson IJ (1999) Development and validation of a core outcome measure for palliative care: the palliative care outcome scale. Qual Health Care 8:219–227 Hearn J, Higginson IJ (1999) Development and validation of a core outcome measure for palliative care: the palliative care outcome scale. Qual Health Care 8:219–227
3.
Zurück zum Zitat Rees E, Hardy J, Ling J, Broadley K, A’Hern R (1998) The use of the Edmonton Symptom Assessment Scale (ESAS) within a palliative care unit in the UK. Palliat Med 12:75–82 Rees E, Hardy J, Ling J, Broadley K, A’Hern R (1998) The use of the Edmonton Symptom Assessment Scale (ESAS) within a palliative care unit in the UK. Palliat Med 12:75–82
4.
Zurück zum Zitat Hardy J, Edmonds P, Turner R, Rees E, A’Hern R (1999) The use of the Rotterdam Symptom Checklist in Palliative Care. J Pain Symp Manag 18 (2):79–84 Hardy J, Edmonds P, Turner R, Rees E, A’Hern R (1999) The use of the Rotterdam Symptom Checklist in Palliative Care. J Pain Symp Manag 18 (2):79–84
5.
Zurück zum Zitat Slevin ML, Plant H, Lynch D, Drinkwater J, Gregory WM (1988) Who should measure quality of life, the doctor or the patient? Br J Cancer 57:109–112 Slevin ML, Plant H, Lynch D, Drinkwater J, Gregory WM (1988) Who should measure quality of life, the doctor or the patient? Br J Cancer 57:109–112
6.
Zurück zum Zitat Higginson IJ, McCarthy M (1993) Validity of the support team assessment schedule: do staff’s rating reflect those made by patients or their families? Palliat Med 7:219–228 Higginson IJ, McCarthy M (1993) Validity of the support team assessment schedule: do staff’s rating reflect those made by patients or their families? Palliat Med 7:219–228
7.
Zurück zum Zitat Field D, Douglas C, Jagger C et al (1995) Terminal illness: views of patients and their lay carers. Palliat Med 9:45–54 Field D, Douglas C, Jagger C et al (1995) Terminal illness: views of patients and their lay carers. Palliat Med 9:45–54
8.
Zurück zum Zitat Chochinov HM, Hack T, Hassard T, Kristjanson LJ, McClement S, Harlos M (2002) Dignity in the terminally ill: a cross-sectional, cohort study. Lancet 360:2026–2030 Chochinov HM, Hack T, Hassard T, Kristjanson LJ, McClement S, Harlos M (2002) Dignity in the terminally ill: a cross-sectional, cohort study. Lancet 360:2026–2030
Metadaten
Titel
Experience in the use of the palliative care outcome scale
verfasst von
A.-M. Stevens
B. Gwilliam
R. A’Hern
K. Broadley
J. Hardy
Publikationsdatum
01.12.2005
Erschienen in
Supportive Care in Cancer / Ausgabe 12/2005
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-005-0815-6

Weitere Artikel der Ausgabe 12/2005

Supportive Care in Cancer 12/2005 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.